Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X about a recent paper by Solange Peters et al. published in Journal of Thoracic Oncology:

“Long-term outcomes of Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC and tumor PD-L1 lower than 1% provides a long-term, durable clinical benefit, with or without chemotherapy, according to Peters S et al. via Journal of Thoracic Oncology.”

“Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis”

Authors: Solange Peters, Luis Paz-Ares, Martin Reck, Diederik Grootendorst, Suresh Ramalingam et al.

Estela Rodriguez: Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC

More posts featuring Estela Rodriguez.